Overcoming severe adverse reactions to venom immunotherapy using anti‐Ig<scp>E</scp> antibodies in combination with a high maintenance dose

Abstract

Combining a temporary omalizumab therapy with an elevated maintenance dose seems a promising approach to achieve a tolerance of treatment in patients with a recurrent SAR to VIT.